Clinical trials of intranasal mupirocin and/or chlorhexidine body wash as the primary intervention for the prevention and control of MRSA colonisation (both intra- and extra-nasal) were eligible for inclusion. Trials of antibiotics or isolation procedures were excluded.
The outcomes reported in the review were the incidence of MRSA colonisation and infection.
All but one of the included trials focused on hospital- or nursing-home-acquired MRSA. The range of hospital settings included intensive care, orthopaedic surgery, gastroenterology, and/or medical units. One trial was conducted in the community among army personnel. Inclusion criteria varied with respect to MRSA status, but most trials included both MRSA-carriers and non-colonised participants. The intervention, in most cases, involved intranasal mupirocin with antiseptic body washes, which were given in varying regimes ranging from three to seven days (where stated). Control conditions included less intensive forms of the intervention, placebo or no treatment. The trials were conducted in Europe, the USA and Japan.
The author did not state how the papers were selected for the review or how many reviewers performed the selection.